Current status of PET-imaging probes of β-amyloid plaques

被引：0
作者：
JaeHyung Koo
Youngjoo Byun
机构：
[1] Daegu Gyeongbuk Institute of Science & Technology (DGIST),Department of Brain Science
[2] Korea University,College of Pharmacy
来源：
Archives of Pharmacal Research | 2013年 / 36卷
关键词：
Amyloid plaques; PET-imaging; Alzheimer's disease;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Alzheimer’s disease (AD) is the most common form of dementia and is characterized by progressive cognitive decline and memory loss. One of pathological hallmarks of AD is the accumulation and deposition of β-amyloid (Aβ) plaques which is a potential target for the early diagnosis of AD. Positron emission tomography (PET), a sensitive radionuclide imaging technique, has provided opportunities to detect Aβ plaques of AD. PET-imaging probes of Aβ plaques have been extensively developed during the last decade. [18F]Florbetapir, the 18F-labeled PET-imaging probe of Aβ plaques, was recently approved by US Food and Drug Administration. A number of follow-on PET-imaging probes are currently being developed in academia and pharmaceutical companies. This article will discuss the recent development of PET-imaging probes from [11C]PIB to [18F]Florbetapir, which are in clinic trials, and several follow-on probes in preclinical stage.
引用
收藏
页码：1178 / 1184
页数：6
相关论文
共 316 条
[1]  
Akiyama H(2000)Inflammation and Alzheimer’s disease Neurobiology of Aging 21 383-421
[2]  
Barger S(1907)Uber eine eigenartige Erkrankung der Hirnrinde Allgemeine Zeitschrift fur Psychiatrie und Psychisch-gerichtliche Medizin 64 146-148
[3]  
Barnum S(2012)Preclinical characterization of a novel class of F-18-labeled PET tracers for amyloid-beta Journal of Nuclear Medicine 53 1794-1801
[4]  
Bradt B(2010)The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer’s disease: oligomer size or conformation? Alzheimers Research and Therapy 2 12-631
[5]  
Bauer J(2012)Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment European Journal of Nuclear Medicine and Molecular Imaging 39 621-13175
[6]  
Cole GM(1996)Evidence that the 42- and 40-amino acid forms of amyloid beta protein are generated from the beta-amyloid precursor protein by different protease activities Proceedings of the National Academy of Sciences USA 93 13170-9145
[7]  
Cooper NR(2012)Novel F-18-labeled benzoxazole derivatives as potential positron emission tomography probes for imaging of cerebral beta-amyloid plaques in Alzheimer’s disease Journal of Medicinal Chemistry 55 9136-9296
[8]  
Eikelenboom P(2012)Synthesis and evaluation of novel F-18 labeled 2-pyridinylbenzoxazole and 2-pyridinylbenzothiazole derivatives as ligands for positron emission tomography (pet) imaging of beta-amyloid plaques Journal of Medicinal Chemistry 55 9283-2132
[9]  
Emmerling M(2009)Microglia activated with the toll-like receptor 9 ligand CpG attenuate oligomeric amyloid beta neurotoxicity in in vitro and in vivo models of Alzheimer’s disease American Journal of Pathology 175 2121-266
[10]  
Fiebich BL(2011)Inflammation and oxidative damage in Alzheimer’s disease: friend or foe? Frontiers in Bioscience (Scholar Edition) 3 252-24
12345678910